Tilray Brands (TLRY) Debt to Equity (2017 - 2026)

Tilray Brands (TLRY) reported Debt to Equity of $0.09 for Q1 2026, up 5.08% quarter-over-quarter from $0.09 in Q4 2025.

Tilray Brands (TLRY) Debt to Equity (2017 - 2026) Analysis & Trends

Tilray Brands has reported Debt to Equity for 10 years, with the latest figure at $0.09 in Q1 2026.

For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to $0.09; the trailing twelve-month figure through Feb 2026 stood at $0.09 (changed N/A YoY), and the FY2025 full-year result was $0.11, up 117.37% from the prior year.
Debt to Equity for Q1 2026 stood at $0.09, up from $0.09 in the prior quarter.
The five-year high for Debt to Equity was $0.11 in Q2 2025, with the low at $0.03 in Q3 2022.
Historically, Debt to Equity has averaged $0.06 across 5 years, with a median of $0.05 in 2023.
Annual changes were most pronounced in 2023 — Debt to Equity jumped 120.05% — and 2024, when it sank 50.83%.
Tilray Brands' Debt to Equity stood at $0.04 in 2022, then jumped by 120.05% to $0.09 in 2023, then tumbled by 50.83% to $0.04 in 2024, then jumped by 108.12% to $0.09 in 2025, then advanced by 5.08% to $0.09 in 2026.
The last three Debt to Equity figures came in at $0.09 (Q1 2026), $0.09 (Q4 2025), and $0.11 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	2.02
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	2.80
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	-
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	0.01
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	-
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	0.61
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	0.86
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	0.47
10	Tilray Brands	-	-	54.95 Mn	0.09

Download Data